Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCPH POWR Grades
- Growth is the dimension where DCPH ranks best; there it ranks ahead of 90.59% of US stocks.
- The strongest trend for DCPH is in Growth, which has been heading up over the past 177 days.
- DCPH ranks lowest in Momentum; there it ranks in the 3rd percentile.
DCPH Stock Summary
- Of note is the ratio of DECIPHERA PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 16.95% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for DECIPHERA PHARMACEUTICALS INC is higher than it is for about only 13.91% of US stocks.
- DCPH's price/sales ratio is 10.76; that's higher than the P/S ratio of 90.21% of US stocks.
- Stocks that are quantitatively similar to DCPH, based on their financial statements, market capitalization, and price volatility, are GOOD, SYPR, ARES, FMNB, and CHT.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Valuation Summary
- In comparison to the median Healthcare stock, DCPH's price/sales ratio is 138.71% higher, now standing at 11.1.
- Over the past 61 months, DCPH's EV/EBIT ratio has gone up 9.3.
Below are key valuation metrics over time for DCPH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCPH | 2022-09-23 | 11.1 | 3.0 | -4.7 | -4.4 |
| DCPH | 2022-09-22 | 11.4 | 3.1 | -4.8 | -4.5 |
| DCPH | 2022-09-21 | 11.3 | 3.0 | -4.8 | -4.5 |
| DCPH | 2022-09-20 | 11.6 | 3.1 | -4.9 | -4.6 |
| DCPH | 2022-09-19 | 11.4 | 3.1 | -4.8 | -4.5 |
| DCPH | 2022-09-16 | 11.3 | 3.0 | -4.8 | -4.5 |
DCPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCPH has a Quality Grade of D, ranking ahead of 19.93% of graded US stocks.
- DCPH's asset turnover comes in at 0.137 -- ranking 232nd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DCPH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.137 | 0.980 | -0.586 |
| 2021-03-31 | 0.104 | 0.993 | -0.553 |
| 2020-12-31 | 0.062 | 0.995 | -0.544 |
| 2020-09-30 | 0.033 | 0.996 | -0.556 |
| 2020-06-30 | 0.011 | 0.999 | -0.565 |
| 2020-03-31 | 0.044 | 1.000 | -0.565 |
DCPH Price Target
For more insight on analysts targets of DCPH, see our DCPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $68.50 | Average Broker Recommendation | 1.36 (Strong Buy) |
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $17.62 | 52-week high | $20.88 |
| Prev. close | $18.25 | 52-week low | $6.51 |
| Day low | $17.36 | Volume | 826,200 |
| Day high | $18.21 | Avg. volume | 1,182,422 |
| 50-day MA | $16.26 | Dividend yield | N/A |
| 200-day MA | $11.63 | Market Cap | 1.18B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Earns Price Target Bump With Encouraging ESMO PresentationDeciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of DCC-3116 in advanced or metastatic tumors with a mutant RAS or RAF gene. Fourteen patients were evaluable for response; the best overall response was stable disease and the disease control rate at week 16 was 29%. HC Wainwright believes the data sets up the potential for future positive data in combination with multiple small molecule targeted therapi |
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022WALTHAM, Mass., September 11, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced updated results from the ongoing Phase 1/2 study of vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of CSF1R, for the treatment of patients with tenosynovial giant cell tumor (TGCT) not amenable to |
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022WALTHAM, Mass., September 10, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced positive initial data from the single agent dose escalation portion of the Phase 1 study of DCC-3116, the Company’s first-in-class, potent, and selective small molecule switch-control kinase inhibitor of ULK1/2, in patients with advanced or metasta |
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022WALTHAM, Mass., September 01, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will host a virtual investor event to review clinical data from the Company’s DCC-3116 and vimseltinib programs to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2022 on Sunday, September 11, 2022, from 7 |
Deciphera (DCPH) Thrives on Qinlock, Overdependence a ConcernDeciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe. |
DCPH Price Returns
| 1-mo | 8.56% |
| 3-mo | 32.88% |
| 6-mo | 77.80% |
| 1-year | 107.42% |
| 3-year | 113.32% |
| 5-year | 271.14% |
| YTD | 80.35% |
| 2021 | -31.52% |
| 2020 | -8.31% |
| 2019 | 196.52% |
| 2018 | -7.41% |
| 2017 | N/A |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...